Eta Atolia

Founder @ TareBio (YC S26) | Spinning out a vaccine discovery platform from immune imprints

Founder

TareBio· Summer 2026Los Angeles Metropolitan Area

in LinkedIn 𝕏 @eatolia

2025Founder· TareBio (YC S26)

Founder · since 2025

Company

TareBio (YC S26)

Role

Founder, CEO

current

Stage

—

no public source

Raised

—

no public source

Based

—

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

TareBio

Vaccines for any cancer or infection in weeks.

Summer 2026

Experience

Career

TareBio (YC S26)
Founder
Founder, CEO · 2025 – Present
2025
UCLA-Caltech Medical Scientist Training Program
MD-PhD Candidate · Los Angeles, California, United States · 2016 – 2025
2016
Harvard Medical School
Undergraduate / Postgraduate Researcher, Goldberg Lab, HMS/MGH · Cambridge, Massachusetts, United States · 2015 – 2016
2015
Massachusetts Institute of Technology
Undergraduate Researcher, Bhatia Lab, Koch Institute · 2011 – 2015
2011
Massachusetts Institute of Technology
Undergraduate Researcher, Wittrup Lab, Koch Institute · 2014
2014
Massachusetts Institute of Technology
iGEM Team Researcher, Weiss Lab, Synthetic Biology Center · 2012
2012
Weizmann Institute of Science
Summer Research Assistant, Eisenbach Lab, Department of Immunology · Reẖovot, Israel · 2011
2011
National High Magnetic Field Laboratory
Research Assistant, Ion Cyclotron Resonance Department · Tallahassee, Florida, United States · 2010 – 2011
2010

Bio

Founder & CEO, TareBio (YC S26). MD-PhD from UCLA-Caltech, where she built a novel platform that develops vaccines for any cancer or infection in weeks, funded by the Gates Foundation. BS in Biology from MIT. Conducted research at the Koch Institute, Harvard Medical School, and the Weizmann. Select Awards: UCLA MD-PhD Merit Scholar, UCLA TDG Senior Fellow, MIT iGEM Gold Medal, MIT IDEAs winner, MIT Dean Advisory Group, WhiteHouse Science Fair, Bessie Lawrence Scholar, Intel STS Finalist